Alterations and interactions of subcortical modulatory systems in Alzheimer's disease (CROSBI ID 69293)
Prilog u knjizi | stručni rad | međunarodna recenzija
Podaci o odgovornosti
Babić Leko, Mirjana ; Hof, Patrick R. ; Šimić, Goran
engleski
Alterations and interactions of subcortical modulatory systems in Alzheimer's disease
The pathogenesis of Alzheimer's disease (AD) is not fully understood. Here we summarize current knowledge on the involvement of the serotonergic, noradrenergic, dopaminergic, cholinergic, and opioid systems in AD, emphasizing the importance of interactions between the serotonergic and the other subcortical modulatory systems during the progression of AD. In physiological conditions, all neurotransmitter systems function in concert and are interdependent at both the neuroanatomical and molecular levels. Through their early involvement in AD, cognitive and behavioral abilities that rely on their interactions also become disrupted. Considering that serotonin (5HT) regulates the release of noradrenaline (NA), dopamine (DA) and acetylcholine (ACh), any alteration in 5HT levels leads to disturbance of NA, DA, and ACh homeostasis in the brain. One of the earliest pathological changes during the prodromal phase of AD is a decrease of serotonergic transmission throughout the brain, with serotonergic receptors being also affected. Additionally, serotonergic and noradrenergic as well as serotonergic and dopaminergic nuclei are reciprocally interconnected. As the serotonergic dorsal raphe nucleus (DRN) is affected by pathological changes early in AD, and the noradrenergic locus coeruleus (LC) and dopaminergic ventral tegmental area (VTA) exhibit AD-related pathological changes, their connectivity also becomes altered in AD. Such disrupted interactions among neurotransmitter systems in AD can be used in the development of multi-target drugs. Some of the potential AD therapeutics (such as ASS234, RS67333, tropisetron) target multiple neurotransmitter systems to achieve the best possible improvement of cognitive and behavioral deficits observed in AD. Here, we review how serotonergic system interacts with other subcortical modulatory systems (noradrenergic, dopaminergic, cholinergic, and opioid systems) during AD.
5-hydroxytryptamine (serotonin) ; acetylcholine ; Alzheimer's disease ; dopamine ; interaction ; noradrenaline ; opioids
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
379-421.
objavljeno
10.1016/bs.pbr.2020.07.016
Podaci o knjizi
5-HT interaction with other neurotransmitters: experimental evidence and therapeutic relevance - Part B
Di Giovanni, Guiseppe ; De Deurwaerdere, Philippe
Amsterdam: Elsevier
2021.
978-0-444-64258-5
0079-6123
1875-7855